Cardiovascular Treatments and Outcomes

Moderator(s)

• 

  Jonathan Slaughter, MD, MPH

  Professor
  Nationwide Children's Hospital and The Ohio State University
  Columbus, United States
• NP

  Nicole Pratt, FISPE

  Professor
  Quality Use of Medicines and Pharmacy Research Centre, University of South Australia
  Adelaide, Australia

Presentations:

• 1:30 PM – 1:45 PM CEST

  Emulating a target trial to avoid immortal time-bias in the estimation of PCSK9 inhibitor effects post myocardial infarction: Methodological opportunities and challenges
  

  Presenting Author: Thomas Cars – Sence Research BV

  Co-Author: Stefan Gustafsson – Sence Research BV

  Co-Author: Queenie Chan, MEng, MSc, PhD – Center for Observational Research, Amgen Ltd

  Co-Author: Nafeesa Dhalwani – Center for Observational Research, Amgen Inc

  Co-Author: Shia T. Kent, PhD – Center for Observational Research, Amgen Inc

  Co-Author: Johan Sundstrom – Department of Medical Sciences, Uppsala University

  Co-Author: Emil Hagstrom – Uppsala Clinical Research Center

  Co-Author: M. Alan Brookhart, PhD – Target RWE
• 1:45 PM – 2:00 PM CEST

  Association between Denosumab and Risk of Cardiovascular Events in Patient with Osteoporosis: A Target Trial Emulation Study with Clone-Censor-Weight Approach
  

  Presenting Author: Albert Tzu-Ming Chuang, PharmD – National Cheng Kung University

  Co-Author: Huei-Kai Huang, MD PhD (he/him/his) – Department of Family Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan

  Co-Author: Peter Ping-Sung Liu, MS – Center for Healthy Longevity, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.

  Co-Author: Tzu-Chi Liao, MS – School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

  Co-Author: Shih-Chieh Shao, PhD – Keelung Chang Gung Memorial Hospital

  Co-Author: Edward Chia-Cheng Lai, PhD (he/him/his) – Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Taiwan
• 2:00 PM – 2:15 PM CEST

  Assessing treatment effectiveness when no appropriate comparator exists: low-density lipoprotein cholesterol lowering therapy (LLT) for the prevention of aortic stenosis (AS) as a case example
  

  Co-Author: Dana J. Murdock, MPH, PhD – Regeneron Pharmaceuticals, Inc.

  Co-Author: Li Wang – Regeneron Pharmaceuticals, Inc.

  Co-Author: Robert Sanchez – Regeneron Pharmaceuticals, Inc.

  Co-Author: Caitlin Knox, PhD MPH FISPE (she/her/hers) – Regeneron Pharmaceuticals

  Co-Author: Kusha Mohammadi – Regeneron Pharmaceuticals, Inc.

  Co-Author: Gregory P. Geba, MD, DrPH – Regeneron Pharmaceuticals, Inc.

  Co-Author: Sergio Fazio – Regeneron Pharmaceuticals, Inc.

  Presenting Author: Jessica J. Jalbert, PhD (she/her/hers) – Regeneron Pharmaceuticals, Inc.
• 2:15 PM – 2:30 PM CEST

  Emulating a target trial for assessing the comparative effectiveness of a newly marketed medication: the example of angiotensin-neprilysin inhibitor in patients with heart failure
  

  Presenting Author: Géric Maura, PhD – Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

  Co-Author: Pierre-Olivier Blotière – Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

  Co-Author: Edouard L. Fu – Leiden University Medical Center

  Co-Author: Juan J. Carrero – Department of Medical Epidemiology and Biostatistics, Karolinska Institutet
• 2:30 PM – 2:45 PM CEST

  Skin Cancer Risk Associated With Statin Treatment: A Target Trial Emulation Study
  

  Presenting Author: Ping Sheng Chou – School of Pharmacy, College of Medicine, National Cheng Kung University, Tainan, Taiwan

  Co-Author: Avery Shuei-He Yang, MClinicpharm – Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Taiwan

  Co-Author: Edward Chia-Cheng Lai, PhD (he/him/his) – Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Taiwan
• 2:45 PM – 3:00 PM CEST

  Risk of Cardiovascular Events, Malignancy, and Serious Infection Associated With JAK inhibitors and TNF inhibitors in Rheumatoid Arthritis or Ulcerative Colitis: A Nationwide Cohort Study
  

  Presenting Author: Yongtai Cho, PharmD – School of Pharmacy, Sungkyunkwan University, Suwon, South Korea

  Co-Author: Dongwon Yoon, PharmD, PhD (he/him/his) – National Institute on Aging, National Institutes of Health

  Co-Author: Farzin Khosrow-Khavar, PhD – Rutgers University

  Co-Author: Minkyo Song – Laboratory of Epidemiology and Population Sciences, National Institute on Aging, National Institutes of Health, Maryland, United States of America

  Co-Author: Ju Hwan Kim, PharmD, PhD – School of Pharmacy, Sungkyunkwan University, Suwon, South Korea

  Co-Author: Ju-Young Shin, PhD – School of Pharmacy, Sungkyunkwan University, Suwon, South Korea